<DOC>
	<DOCNO>NCT00831597</DOCNO>
	<brief_summary>A phase II trial evaluate efficacy safety combination bendamustine rituximab patient relapse refractory diffuse large B-cell lymphoma . It hypothesize BR combination produce least 70 % overall response rate .</brief_summary>
	<brief_title>Bendamustine Combined With Rituximab Patients With Relapsed Refractory Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically confirm CD20positive , diffuse large Bcell lymphoma Measurable disease least one bidimensional lymph node tumor mass &gt; 1.5 cm long diameter follow response target lesion measure PET CT Relapsed refractory least one prior therapeutic treatment diffuse large Bcell lymphoma . Relapsed defined patient initially respond progress . Refractory define patient , judgment Investigator , receive adequate prior treatment respond treatment progress within 60 day last treatment . Relapse follow autologous stem cell transplant allow . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 02 Patient must understand voluntarily sign IRBapproved inform consent Life expectancy ≥ three ( 3 ) month Age ≥ 18 year old Laboratory parameter : Absolute neutrophil count ≥ 1,000 cells/mm ( 3 ) Platelet count ≥ 75,000 cells/mm ( 3 ) Hemoglobin ≥ 8 g/dL Creatinine ≤ 2.0 mg/dL Creatinine Clearance ≥ 50 mL/min ( calculated 24hr urine sample ) AST/SGOT 2.0 x ULN ( ≤ 5.0 x ULN secondary liver metastasis ) ALT/SGPT 2.0 x ULN ( ≤ 5.0 x ULN secondary liver metastasis ) Total bilirubin ≤ 2.0 x ULN Patients active/symptomatic central nervous system ( CNS ) involvement base clinical evaluation . Previously treat CNS involvement remain asymptomatic ≥ 90 day allow CNS involvement show lumbar puncture , PET , CT MRI . Prior treatment bendamustine Known sensitivity bendamustine component bendamustine Known anaphylaxis immunoglobulin E ( IgE ) mediate hypersensitivity murine proteins sensitivity rituximab component rituximab Eligible stem cell transplant ( patient refuse procedure exclude ) Prior allogeneic stem cell transplant within 6 month Cycle 1 , Day 1 Major surgery , relate debulking procedure , within 21 day Cycle 1 , Day 1 . Patients undergo debulking procedure minor surgery allow recovery period , judgment Investigator . Chemotherapy , immunotherapy , irradiation within 28 day Cycle 1 , Day 1 ( within 6 week nitrosoureas mitomycin ) . Patients high dose corticosteroid must taper stable dose equivalent Prednisone ≤ 15 mg per day within 28 day Cycle 1 , Day 1 . Prior radioimmunotherapy ( i.e . Zevalin® ) within 10 week Cycle 1 , Day 1 Prior use investigational anticancer agent within 28 day Cycle 1 , Day 1 Unresolved toxicity ≥ grade 2 previous therapy Pregnant lactating female . Females childbearing potential ( FCBP ) nonvasectomized men must agree use effective method birth control 28 day follow treatment period . FCBP must negative pregnancy test . HIVrelated lymphoma Known active HIV HCV infection , know seropositivity HIV , current chronic HBV HCV infection . HBV test require screening within 6 month screen must indicate negative result . Patients seropositivity presume due prior vaccination Hepatitis B resolve infection exclude ( see HBV reactivation guideline include rituximab prescribe information ) . Concurrent active history malignancy , except nonmelanoma skin cancer carcinoma situ cervix breast . Patients previous malignancy eligible provide disease free ≥ 1 year . Serious ( grade 34 ) , active , intercurrent infection require therapy , deep seat systemic mycotic infection Myocardial infarction within 6 month prior registration New York Hospital Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia significant conduction system abnormality , judgment Investigator Thyroid disease thyroid function maintain within normal range , judgment Investigator Concurrent uncontrolled serious medical psychiatric condition likely interfere participation clinical study , judgment Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>B-Cell</keyword>
</DOC>